Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
McKesson
Dow
Express Scripts
Moodys

Last Updated: January 31, 2023

Investigational Drug Information for Surufatinib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Surufatinib?

Surufatinib is an investigational drug.

There have been 54 clinical trials for Surufatinib. The most recent clinical trial was a Phase 2 trial, which was initiated on December 7th 2015.

The most common disease conditions in clinical trials are Carcinoma, Neuroendocrine Tumors, and Neoplasms. The leading clinical trial sponsors are Hutchison Medipharma Limited, Sun Yat-sen University, and Fujian Cancer Hospital.

There are four US patents protecting this investigational drug and forty-six international patents.

Recent Clinical Trials for Surufatinib
TitleSponsorPhase
Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLCBeijing Chest HospitalPhase 2
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerBai-Rong XiaPhase 2
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix CarcinomaSun Yat-sen UniversityPhase 2

See all Surufatinib clinical trials

Clinical Trial Summary for Surufatinib

Top disease conditions for Surufatinib
Top clinical trial sponsors for Surufatinib

See all Surufatinib clinical trials

US Patents for Surufatinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Surufatinib See Plans and Pricing Stable, concentrated radionuclide complex solutions ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (Pozzilli (Isernia), IT) See Plans and Pricing
Surufatinib See Plans and Pricing Stable, concentrated radionuclide complex solutions ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (Pozzilli (Isernia), IT) See Plans and Pricing
Surufatinib See Plans and Pricing Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use Hutchison MediPharma Limited (Shanghai, CN) See Plans and Pricing
Surufatinib See Plans and Pricing Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use Hutchison Medipharma Limited (Shanghai, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Surufatinib

Drugname Country Document Number Estimated Expiration Related US Patent
Surufatinib Argentina AR119655 2038-07-25 See Plans and Pricing
Surufatinib Australia AU2018433575 2038-07-25 See Plans and Pricing
Surufatinib Australia AU2022203683 2038-07-25 See Plans and Pricing
Surufatinib Brazil BR112021001148 2038-07-25 See Plans and Pricing
Surufatinib Canada CA3153630 2038-07-25 See Plans and Pricing
Surufatinib China CN112584875 2038-07-25 See Plans and Pricing
Surufatinib China CN112867512 2038-07-25 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
McKesson
Dow
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.